TORRANCE, Calif.--BUSINESS WIRE--Celprogen Inc., a leader in the Stem Cell Research / Therapeutics industry and Oncology Drug discovery since 2002, today announced they successfully completed their pre-clinical evaluation of CEP1430 and CEP1507 compounds as selectively targeting Pancreatic Cancer stem Cell population that contribute to treatment related resistance. Both compounds demonstrated growth inhibition of pancreatic tumors in patient derived xenograft PDX cancer models by 80% to 85%. The results of the study will be presented in an abstract format on Monday, April 18, 2016 at American Association of Cancer Research (AACR) annual meeting in New Orleans. These compounds are Celprogen’s propriety compounds for targeting Pancreatic Cancer Stem Cells (CSC) and Circulating Tumor Cells CTC in patients with advanced stages of pancreatic cancer.
The present invention relates to Drug Discovery programs at Celprogen that identify potential drug candidates for the treatment of pancreatic cancer. At present Celprogen is exploring partnership with Pharmaceutical Industry to move promising drug candidates forward to the clinical development and increasing the armament of drugs against pancreatic cancer. CEP1430 is a selective inhibitor of CSC that can be administrated orally and does not exhibit sign of toxicity. The mechanism of cell death also indicates that these molecules will greatly enhance the efficacy of immune based approaches to improve outcome in pancreatic cancer patients. These pancreatic Stem Cell selective inhibitors are expected to eradicate tumors, improve quality of life and prolong and/or overall survival and patients bearing pancreatic tumors.